Geode Capital Management LLC Increases Stock Position in Cue Biopharma, Inc. (NASDAQ:CUE)

Geode Capital Management LLC increased its position in shares of Cue Biopharma, Inc. (NASDAQ:CUE) by 3.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 508,827 shares of the company’s stock after purchasing an additional 16,371 shares during the quarter. Geode Capital Management LLC owned approximately 1.05% of Cue Biopharma worth $385,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Sigma Planning Corp raised its position in Cue Biopharma by 50.9% in the third quarter. Sigma Planning Corp now owns 401,325 shares of the company’s stock worth $304,000 after acquiring an additional 135,295 shares during the period. Good Life Advisors LLC lifted its stake in Cue Biopharma by 23.1% in the third quarter. Good Life Advisors LLC now owns 400,000 shares of the company’s stock valued at $303,000 after purchasing an additional 75,000 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Cue Biopharma during the second quarter valued at $66,000. Finally, GSA Capital Partners LLP increased its position in Cue Biopharma by 5.1% in the third quarter. GSA Capital Partners LLP now owns 291,663 shares of the company’s stock worth $221,000 after buying an additional 14,104 shares during the last quarter. 35.04% of the stock is owned by institutional investors.

Cue Biopharma Stock Up 4.1 %

Shares of NASDAQ CUE opened at $1.51 on Monday. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.22 and a quick ratio of 2.22. The stock has a market capitalization of $95.66 million, a PE ratio of -1.68 and a beta of 1.63. Cue Biopharma, Inc. has a one year low of $0.45 and a one year high of $3.20. The business’s fifty day moving average price is $1.24 and its 200-day moving average price is $1.02.

Insider Activity at Cue Biopharma

In related news, CEO Daniel R. Passeri purchased 30,000 shares of the business’s stock in a transaction dated Monday, December 16th. The stock was purchased at an average cost of $1.03 per share, with a total value of $30,900.00. Following the completion of the acquisition, the chief executive officer now directly owns 164,578 shares of the company’s stock, valued at approximately $169,515.34. The trade was a 22.29 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 12.26% of the stock is currently owned by company insiders.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.